Literature DB >> 23820101

Hypnotic and sedative drugs--anything new on the horizon?

Tony Gin1.   

Abstract

PURPOSE OF REVIEW: Many studies of new intravenous sedative drugs have been published last year, including several phase I trials. This review provides a brief summary of these studies, with recommendations for selected reading. RECENT
FINDINGS: Remimazolam is a rapidly metabolized benzodiazepine. Early clinical trials confirm more rapid recovery compared with midazolam. Etomidate analogues can be designed with rapid metabolism and without adrenocortical suppression, but research is only at the preclinical stage. MR04A3 and AZD3043 are gamma-aminobutyric acid A agonists with phase I data, but the outlook for further development is uncertain. Pioneers of intravenous emulsions of volatile anesthetics continue their work.
SUMMARY: Many of the new sedative drugs were designed to undergo rapid metabolism. Remimazolam has great potential to enter clinical practice because of its rapid offset of action.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23820101     DOI: 10.1097/ACO.0b013e328362a7a3

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  3 in total

1.  Etomidate in sepsis: understanding the dilemma.

Authors:  David J Gagnon; David B Seder
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

2.  Anesthetic management using remimazolam in a patient with atrial flutter: a case report.

Authors:  Joo Yong Lee; Hyeon Tae Kim; Yae Jee Kim; Jin Sol Lee; Jin Wook Park; Young Duck Shin
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

3.  Risk factor analyses for the return of spontaneous circulation in the asphyxiation cardiac arrest porcine model.

Authors:  Cai-Jun Wu; Zhi-Jun Guo; Chun-Sheng Li; Yi Zhang; Jun Yang
Journal:  Chin Med J (Engl)       Date:  2015-04-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.